TEVA — Teva Pharmaceutical Industries Balance Sheet
0.000.00%
HealthcareBalancedMicro Cap
Annual balance sheet for Teva Pharmaceutical Industries, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2,177 | 2,165 | 2,801 | 3,226 | 3,300 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,581 | 4,529 | 3,696 | 3,408 | 3,059 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 13,005 | 12,573 | 12,051 | 12,486 | 12,552 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6,855 | 6,477 | 6,158 | 6,147 | 4,948 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 50,640 | 47,666 | 44,011 | 43,480 | 39,326 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 13,164 | 11,027 | 11,469 | 12,247 | 12,796 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 40,614 | 37,388 | 36,207 | 35,973 | 33,953 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 10,026 | 10,278 | 7,804 | 7,506 | 5,373 |
| Total Liabilities & Shareholders' Equity | 50,640 | 47,666 | 44,011 | 43,479 | 39,326 |
| Total Common Shares Outstanding |